ORNBV Orion Oyj Class B

Orion Corporation: Organising meeting of the Board of Directors

Orion Corporation: Organising meeting of the Board of Directors

ORION CORPORATION

STOCK EXCHANGE RELEASE / OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE

22 MARCH 2023 at 17.15 EET              

        

Orion Corporation: Organising meeting of the Board of Directors

In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Hilpi Rautelin as Vice Chair.

The compositions of the Board committees were decided to be as follows:



Personnel and Remuneration Committee:

Mikael Silvennoinen, Chair

Maziar Mike Doustdar

Veli-Matti Mattila

Hilpi Rautelin

 

Audit Committee:

Ari Lehtoranta, Chair

Kari Jussi Aho

Eija Ronkainen

Karen Lykke Sørensen

 

R&D Committee:

Hilpi Rautelin, Chair

Kari Jussi Aho

Veli-Matti Mattila

Eija Ronkainen

Karen Lykke Sørensen

 

The Company also has a Nomination Committee, the election of which was announced in a Stock Exchange Release on 29 April 2022. A change in the Nomination Committee composition was announced in a Stock Exchange Release on 21 March 2023.

All members of the Board of Directors have been evaluated to be independent of the company and its significant shareholders.

Orion Corporation

Liisa Hurme



President and CEO
   Olli Huotari



SVP, Corporate Functions
 

                                                

Contact person:

Olli Huotari, Senior Vice President, Corporate Functions

Phone 4

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland



Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.



EN
22/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vin...

Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS1 APRIL 2026 at 16.00 EEST         Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines Orion Corporation (“Orion”) has appointed Berkeley Vincent as Executive Vice President, Innovative Medicines and a member of the Orion Executive Team as of 8 April 2026. The appointment is part of a leadership struc...

 PRESS RELEASE

Muutos Orion-konsernin johtoryhmässä 8.4.2026 lukien – Berkeley Vincen...

Muutos Orion-konsernin johtoryhmässä 8.4.2026 lukien – Berkeley Vincent nimitetty Innovative Medicines -yksikön johtajaksi ORION OYJ        PÖRSSITIEDOTE – MUUTOKSET HALLITUS/JOHTO/TILINTARKASTUS1.4.2026 KLO 16.00         Muutos Orion-konsernin johtoryhmässä 8.4.2026 lukien – Berkeley Vincent nimitetty Innovative Medicines -yksikön johtajaksi Orion-konsernin Innovative Medicines -yksikön johtajaksi ja johtoryhmän jäseneksi on nimitetty 8.4.2026 lukien Berkeley Vincent. Nimitys liittyy organisaation johtamisrakenteen uudistukseen, jossa aiemmin yhdistetty Research & Develo...

 PRESS RELEASE

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securi...

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS31 March 2026 at 18:00 EEST          Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds, and the total number of Orion shares owned directly, indi...

 PRESS RELEASE

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoit...

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) ORION OYJ        PÖRSSITIEDOTE / SUURIMMAT OSAKKEENOMISTAJAT -TIEDOTE        31.3.2026 KLO 18:00         Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) Orion Oyj on saanut Arvopaperimarkkinalain 9. luvun 5 §:n mukaisen ilmoituksen,  jonka mukaan BlackRock, Inc.:n ja sen rahastojen suoraan ja välillisesti omistamien sekä BlackRock, Inc.:n ja sen rahastojen suoraan, välillisesti ja rahoitusvälineiden kautta omistamien Orionin osakkeiden osuus on 30....

 PRESS RELEASE

Decisions taken by Orion Corporation's Annual General Meeting and Boar...

Decisions taken by Orion Corporation's Annual General Meeting and Board of Directors' organising meeting on 24 March 2026 ORION CORPORATION STOCK EXCHANGE RELEASE – DECISIONS OF GENERAL MEETING24 MARCH 2026 at 16.30 EET         Decisions taken by Orion Corporation's Annual General Meeting and Board of Directors' organising meeting on 24 March 2026 At the Annual General Meeting of Orion Corporation held today, the following decisions were made: A dividend of EUR 1.80 per share was confirmed to be paid. The dividend is paid in two instalments.The proposals concerning the election and remun...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch